Loading...
OTCM
NWPHF
Market cap310mUSD
Oct 09, Last price  
9.36
Name

Newron Pharmaceuticals SpA

Chart & Performance

D1W1MN
OTCM:NWPHF chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.27%
Rev. gr., 5y
29.47%
Revenues
19m
-62.78%
1,191,0004,024,0003,933,0002,542,000806,000280,0008,924,0003,539,0001,557,0002,380,0006,726,00013,428,0004,025,0007,038,0005,258,0005,762,0006,094,0009,057,00051,390,00019,126,000
Net income
-13m
L
-16,401,000-11,089,000-16,364,000-23,481,000-20,545,000-6,445,000-2,375,000-7,098,000-10,095,000-22,816,000-15,237,000-5,282,000-15,035,000-20,207,000-20,998,000-14,901,000-17,493,000-16,224,00015,843,000-13,239,000
CFO
33m
P
-9,630,000-13,866,000-19,932,000-23,056,000-19,127,000-4,942,0005,825,000-10,686,000-9,998,000-12,862,000-19,583,000-8,404,000-15,954,000-21,976,000-15,588,000-11,445,000-11,092,000-10,140,000-17,614,00032,560,322

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Founded in 1999 and headquartered in Bresso, Italy, Newron Pharmaceuticals S.p.A. is a clinical-stage biopharmaceutical enterprise focused on discovering and progressing therapeutic solutions. Its primary areas of research and development encompass conditions affecting the central and peripheral nervous systems, alongside pain management, with activities primarily conducted in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease and is also exploring its application for levodopa-induced dyskinesia. Furthermore, Newron is advancing Evenamide for various forms of schizophrenia, including those resistant to existing treatments, and Ralfinamide for the rare disease indication of neuropathic pain.
URL
https://www.newron.com/
IPO date
Dec 12, 2006
Employees
23
Domiciled in
IT
Incorporated in
IT

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT